Jurij Hanžel

1.8k total citations · 1 hit paper
73 papers, 663 citations indexed

About

Jurij Hanžel is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Jurij Hanžel has authored 73 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Genetics, 33 papers in Epidemiology and 19 papers in Immunology. Recurrent topics in Jurij Hanžel's work include Inflammatory Bowel Disease (45 papers), Microscopic Colitis (29 papers) and Biosimilars and Bioanalytical Methods (10 papers). Jurij Hanžel is often cited by papers focused on Inflammatory Bowel Disease (45 papers), Microscopic Colitis (29 papers) and Biosimilars and Bioanalytical Methods (10 papers). Jurij Hanžel collaborates with scholars based in Slovenia, Canada and United States. Jurij Hanžel's co-authors include Geert D’Haens, Christopher Ma, Brian G. Feagan, Vipul Jairath, Rocío Sedaño, Vipul Jairath, K Gecse, David Drobne, Borut Štabuc and Claire E Parker and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Radiology.

In The Last Decade

Jurij Hanžel

64 papers receiving 635 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review

2025 21 citations Rocío Sedaño, Virginia Solitano et al. Therapeutic Advances in Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jurij Hanžel Slovenia	18	433	278	194	149	49	73	663
Maria Kanariou Greece	19	255 0.6×	153 0.6×	300 1.5×	124 0.8×	113 2.3×	54	869
Paul Risley United Kingdom	13	99 0.2×	208 0.7×	245 1.3×	129 0.9×	42 0.9×	15	654
Jochen Klaus Germany	13	277 0.6×	175 0.6×	128 0.7×	125 0.8×	16 0.3×	34	526
G. Luzi Italy	17	144 0.3×	230 0.8×	435 2.2×	109 0.7×	134 2.7×	52	868
Benita K. Book United States	17	69 0.2×	184 0.7×	347 1.8×	268 1.8×	31 0.6×	40	975
Noam Zevit Israel	16	259 0.6×	343 1.2×	120 0.6×	444 3.0×	35 0.7×	54	847
K. Goethals Belgium	15	152 0.4×	61 0.2×	114 0.6×	66 0.4×	22 0.4×	21	665
Konstantin Doberer Austria	16	110 0.3×	159 0.6×	168 0.9×	223 1.5×	47 1.0×	37	789
Minna Sjöroos Finland	15	742 1.7×	93 0.3×	210 1.1×	526 3.5×	28 0.6×	21	1.1k
Victoria Rai United States	12	305 0.7×	219 0.8×	72 0.4×	105 0.7×	19 0.4×	38	529

Countries citing papers authored by Jurij Hanžel

Since Specialization

Citations

This map shows the geographic impact of Jurij Hanžel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jurij Hanžel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jurij Hanžel more than expected).

Fields of papers citing papers by Jurij Hanžel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jurij Hanžel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jurij Hanžel. The network helps show where Jurij Hanžel may publish in the future.

Co-authorship network of co-authors of Jurij Hanžel

This figure shows the co-authorship network connecting the top 25 collaborators of Jurij Hanžel. A scholar is included among the top collaborators of Jurij Hanžel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jurij Hanžel. Jurij Hanžel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sedaño, Rocío, Virginia Solitano, Sudheer K. Vuyyuru, et al.. (2025). Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review. Therapeutic Advances in Gastroenterology. 18. 1128504891–1128504891. 21 indexed citations breakdown →

Solitano, Virginia, Malcolm Hogan, Siddharth Singh, et al.. (2025). Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis. Journal of Crohn s and Colitis. 19(10).

Hanžel, Jurij, Christopher Ma, & Vipul Jairath. (2024). Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease. Immunotherapy. 16(6). 345–357. 1 indexed citations

Pittet, Valérie, Peter Bossuyt, Jurij Hanžel, et al.. (2024). Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review. Journal of Crohn s and Colitis. 18(6). 875–884. 1 indexed citations

Hanžel, Jurij, et al.. (2024). Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina. 60(2). 296–296. 2 indexed citations

Vuyyuru, Sudheer K., Virginia Solitano, Siddharth Singh, et al.. (2023). Scoring Indices for Perianal Fistulising Crohn’s Disease: A Systematic Review. Journal of Crohn s and Colitis. 18(6). 836–850. 10 indexed citations

Hanžel, Jurij, et al.. (2023). Performance of European and American Societies of Gastrointestinal Endoscopy Guidelines for Prediction of Choledocholithiasis in Patients with Acute Biliary Pancreatitis. Medicina. 59(12). 2176–2176. 2 indexed citations

Hanžel, Jurij, Christopher Ma, & Vipul Jairath. (2023). Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis. Immunotherapy. 15(15). 1199–1208. 7 indexed citations

Vuyyuru, Sudheer K., Lisa M. Shackelton, Jurij Hanžel, et al.. (2023). Targeting IL-23 for IBD: Rationale and Progress to Date. Drugs. 83(10). 873–891. 26 indexed citations

10.

Ma, Christopher, Rocío Sedaño, Jurij Hanžel, et al.. (2022). Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis. Journal of Crohn s and Colitis. 17(4). 644–658. 2 indexed citations

11.

Hanžel, Jurij, Peter Bossuyt, Valérie Pittet, et al.. (2022). Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper. Journal of Crohn s and Colitis. 17(3). 311–317. 9 indexed citations

12.

Hanžel, Jurij, Christopher Ma, Neeraj Narula, et al.. (2022). Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies. Journal of Crohn s and Colitis. 17(3). 404–417. 11 indexed citations

13.

Bossuyt, Peter, Valérie Pittet, Jurij Hanžel, et al.. (2022). A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence. Journal of Crohn s and Colitis. 16(10). 1511–1522. 7 indexed citations

14.

Hanžel, Jurij, Alexandra C. Istl, Claire E. Parker, et al.. (2021). Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn’s Disease After Elective Surgery: Meta-Analysis. Digestive Diseases and Sciences. 67(2). 646–660. 5 indexed citations

15.

Hanžel, Jurij, Gregor Novak, Borut Štabuc, et al.. (2021). Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model. Pharmaceutics. 13(10). 1587–1587. 17 indexed citations

16.

Sedaño, Rocío, Malcolm Hogan, Tran M Nguyen, et al.. (2021). Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. Journal of Crohn s and Colitis. 16(2). 224–243. 18 indexed citations

17.

Sedaño, Rocío, Malcolm Hogan, Guangyong Zou, et al.. (2021). Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn’s Disease: Meta-Analysis of Randomised Controlled Trials. Journal of Crohn s and Colitis. 16(5). 717–736. 17 indexed citations

18.

Hanžel, Jurij, Gregor Novak, Borut Štabuc, et al.. (2020). Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission. Clinical Gastroenterology and Hepatology. 19(1). 111–118.e10. 32 indexed citations

19.

Drobne, David, et al.. (2019). Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 49(7). 880–889. 28 indexed citations

20.

Hanžel, Jurij, Ivan Ferkolj, Borut Štabuc, et al.. (2019). Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European Gastroenterology Journal. 7(6). 741–749. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact